BioNTech (NASDAQ:BNTX) Trading Up 2.9% – Still a Buy?

BioNTech SE (NASDAQ:BNTX)’s stock price traded up 2.9% during mid-day trading on Tuesday . The stock traded as high as $117.98 and last traded at $117.49. 136,530 shares were traded during trading, a decline of 83% from the average session volume of 806,539 shares. The stock had previously closed at $114.22.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Morgan Stanley upgraded shares of BioNTech from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $93.00 to $145.00 in a report on Tuesday, September 24th. Bank of America upped their price target on shares of BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, September 16th. Deutsche Bank Aktiengesellschaft upped their price target on shares of BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, September 19th. UBS Group upped their price target on shares of BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a report on Wednesday, September 18th. Finally, Berenberg Bank assumed coverage on shares of BioNTech in a report on Tuesday, November 19th. They set a “buy” rating and a $130.00 price target for the company. Four equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $140.76.

BioNTech Trading Up 3.7 %

The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The firm’s 50 day moving average is $113.72 and its two-hundred day moving average is $100.54. The company has a market cap of $28.17 billion, a P/E ratio of -55.95 and a beta of 0.22.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. During the same period last year, the business posted $0.73 EPS. The business’s revenue was up 38.9% compared to the same quarter last year. As a group, equities research analysts anticipate that BioNTech SE will post -3.72 EPS for the current year.

Institutional Trading of BioNTech

Large investors have recently bought and sold shares of the business. Candriam S.C.A. grew its holdings in BioNTech by 261.2% during the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after acquiring an additional 418,695 shares during the period. Fred Alger Management LLC acquired a new stake in BioNTech during the 3rd quarter worth about $59,485,000. Baillie Gifford & Co. grew its holdings in BioNTech by 0.4% during the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock worth $986,750,000 after acquiring an additional 31,773 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in BioNTech by 63.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company’s stock worth $2,249,000 after acquiring an additional 7,340 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of BioNTech by 123.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company’s stock valued at $15,919,000 after buying an additional 74,119 shares during the period. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.